Patents by Inventor Sharat Singh

Sharat Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES
    Publication number: 20140057367
    Abstract: The present invention provides assays for detecting and measuring the presence or level of anti-TNF? drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.
    Type: Application
    Filed: October 4, 2013
    Publication date: February 27, 2014
    Applicant: NESTEC S.A.
    Inventors: SHARAT SINGH, SHUI LONG WANG, LINDA OHRMUND
  • Antibody-based arrays for detecting multiple signal transducers in rate circulating cells
    Patent number: 8658388
    Abstract: The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: February 25, 2014
    Assignee: Nestec S.A.
    Inventors: Jeanne Harvey, Sharat Singh, Phillip Kim, Xinjun Liu, Robert Barham, Limin Liu
  • MOBILITY SHIFT ASSAYS FOR DETECTING ANTI-TNF ALPHA DRUGS AND AUTOANTIBODIES THERETO
    Publication number: 20140051184
    Abstract: The present invention provides assays for detecting and measuring the presence or level anti-TNF? drugs and/or the autoantibodies to anti-TNF? drugs in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies against the drug. The present invention also provides methods for selecting therapy, optimizing therapy, and/or reducing toxicity in subjects receiving anti-TNF? drugs for the treatment of TNF?-mediated disease or disorders.
    Type: Application
    Filed: March 12, 2013
    Publication date: February 20, 2014
    Inventors: Sharat Singh, Scott Hauenstein, Linda Ohrmund
  • ASSAYS FOR DETECTING AUTOANTIBODIES TO ANTI-TNFALPHA DRUGS
    Publication number: 20140045276
    Abstract: The present invention provides assays for detecting and measuring the presence or level of autoantibodies to anti-TNF? drug therapeutics in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies against the drug. The present invention also provides methods for selecting therapy, optimizing therapy, and/or reducing toxicity in subjects receiving anti-TNF? drugs for the treatment of TNF?-mediated disease or disorders.
    Type: Application
    Filed: August 7, 2013
    Publication date: February 13, 2014
    Inventors: Sharat Singh, Shui Long Wang, Linda Ohrmund, Scott Hauenstein
  • DRUG SELECTION FOR MALIGNANT CANCER THERAPY USING ANTIBODY-BASED ARRAYS
    Publication number: 20140024548
    Abstract: The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of a malignant cancer involving aberrant c-Met signaling. The present invention also provides methods for monitoring the status of a malignant cancer involving aberrant cMet signaling and monitoring how a patient with the malignant cancer is responding to anticancer drug therapy.
    Type: Application
    Filed: June 20, 2013
    Publication date: January 23, 2014
    Inventors: Sharat Singh, Nicholas Hoe, Fred Princen, Xinjun Liu
  • Drug selection for breast cancer therapy using antibody-based arrays
    Patent number: 8609349
    Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: December 17, 2013
    Assignee: Nestec S.A.
    Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
  • DRUG SELECTION FOR COLORECTAL CANCER THERAPY USING RECEPTOR TYROSINE KINASE PROFILING
    Publication number: 20130324430
    Abstract: The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy. The present invention further provides methods for the rational selection of therapy with one or more anticancer drugs tailored to target signal transduction pathway components with dysregulated expression and/or activation levels in patients with somatic mutations in an oncogene.
    Type: Application
    Filed: March 13, 2013
    Publication date: December 5, 2013
    Inventors: Phillip Kim, Sharat Singh
  • APPARATUS AND METHOD FOR ISOLATING LEUKOCYTES AND TUMOR CELLS BY FILTRATION
    Publication number: 20130323711
    Abstract: The present invention provides novel apparatuses and methods for isolating or recovering a subset of blood cells such as leukocytes and/or circulating tumor cells from blood samples by filtration without changing the intracellular concentration of a therapeutic agent such as an anticancer drug. Contrary to the art, the apparatuses and methods of the present invention advantageously provide cell lysates from recovered cells such as leukocytes and/or circulating tumor cells without substantial dilution of a therapeutic agent such as an anticancer drug.
    Type: Application
    Filed: August 7, 2013
    Publication date: December 5, 2013
    Inventors: Sharat Singh, Xinjun Liu, Kelly D. Hester
  • Assays for the detection of anti-TNF drugs and autoantibodies
    Patent number: 8574855
    Abstract: The present invention provides assays for detecting and measuring the presence or level of anti-TNF? drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: November 5, 2013
    Assignee: Nestec S.A.
    Inventors: Sharat Singh, Shui Long Wang, Linda Ohrmund
  • ADDRESSABLE ANTIBODY ARRAYS AND METHODS OF USE
    Publication number: 20130267431
    Abstract: Systems and assay methods are disclosed for detecting an autoantibody in a sample. In certain instances, the systems and methods employ a mass tag releasably connected to an antigen. The tag is thereafter released for detection. A tag can be detected by mass spectrometry or in certain instances the tag is fluorescent. Methods for diagnosing a disease or disorder in a subject are also disclosed.
    Type: Application
    Filed: October 1, 2012
    Publication date: October 10, 2013
    Applicant: Nestec S.A.
    Inventors: Sharat Singh, Shui Long Wang
  • ASSAY FOR DETECTING NEUTRALIZING AUTOANTIBODIES TO BIOLOGIC THERAPY
    Publication number: 20130266963
    Abstract: The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNF? drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 10, 2013
    Inventors: Scott Hauenstein, Sharat Singh
  • DRUG SELECTION FOR GASTRIC CANCER THERAPY USING ANTIBODY-BASED ARRAYS
    Publication number: 20130237436
    Abstract: The present invention provides methods for selecting a suitable anticancer therapy, and for identifying and predicting response for the treatment of a gastric cancer.
    Type: Application
    Filed: January 26, 2011
    Publication date: September 12, 2013
    Applicant: Prometheus Laboratories Inc.
    Inventors: Sharat Singh, Phillip Kim, Xinjun Liu, Belen Ybarrondo
  • Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
    Patent number: 8519096
    Abstract: The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: August 27, 2013
    Assignee: Nestec S.A.
    Inventors: Nicholas Chi-Kwan Ling, Shui Long Wang, Dunrui Wang, Sharat Singh
  • Assays and methods for the detection of Crohn's disease
    Patent number: 8445215
    Abstract: The present invention provides devices and methods for aiding in the diagnosis of Crohn's disease. The devices and methods accurately identify whether a sample from an individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof such as Crohn's disease (CD). The present invention is useful for determining whether a sample from an individual is an IBD sample, or differentiating between CD and ulcerative colitis (UC). Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: May 21, 2013
    Assignee: Nestec S.A.
    Inventors: Shui-Long Wang, Nicholas Chi-Kwan Ling, Sharat Singh
  • DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS
    Publication number: 20130045880
    Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
    Type: Application
    Filed: April 4, 2012
    Publication date: February 21, 2013
    Applicant: Prometheus Laboratories Inc.
    Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
  • METHODS FOR PREDICTING RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER TO THERAPY
    Publication number: 20130012407
    Abstract: The present invention provides compositions and methods for detecting the expression and/or activation levels of components of signal transduction pathways in tumor cells such as triple-negative metastatic breast tumor cells. Information on the expression and/or activation levels of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
    Type: Application
    Filed: July 10, 2012
    Publication date: January 10, 2013
    Applicant: Nestec S.A.
    Inventors: Xinjun Liu, Phillip Kim, Richard Kirkland, Tani Lee, Belen Ybarrondo, Sharat Singh
  • NOVEL GENOMIC BIOMARKERS FOR IRRITABLE BOWEL SYNDROME DIAGNOSIS
    Publication number: 20130005596
    Abstract: The invention provides novel biomarkers, kits, and methods of diagnosing, prognosing, and subtyping IBS. In one aspect, the invention provides novel genomic biomarkers for diagnosing, classifying, providing a prognosis for, and assigning therapy for IBS in a subject in need thereof. In another aspect, the present invention provides novel algorithms for the diagnosis and prognosis of IBS.
    Type: Application
    Filed: May 23, 2012
    Publication date: January 3, 2013
    Applicant: Nestec S.A.
    Inventors: Hua Gong, Sharat Singh, Nicholas Hoe
  • ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES
    Publication number: 20120329172
    Abstract: The present invention provides assays for detecting and measuring the presence or level of anti-TNF? drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.
    Type: Application
    Filed: April 6, 2012
    Publication date: December 27, 2012
    Applicant: Prometheus Laboratories Inc.
    Inventors: Sharat Singh, Shui Long Wang, Linda Ohrmund
  • METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME
    Publication number: 20120315630
    Abstract: The invention provides novel biomarkers, kits, and methods of diagnosing, prognosing, and subtyping IBS. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of novel IBS biomarkers identified herein.
    Type: Application
    Filed: April 6, 2012
    Publication date: December 13, 2012
    Applicant: Prometheus Laboratories Inc.
    Inventors: Hua Gong, Shui Long Wang, Sharat Singh
  • Methods for detecting receptor complexes comprising PI3K
    Patent number: RE44437
    Abstract: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: August 13, 2013
    Assignee: Monogram Biosciences, Inc.
    Inventors: Po-Ying Chan-Hui, Rajiv Dua, Ali Mukherjee, Sailaja Pidaparthi, Hossein Salimi-Moosavi, Yining Shi, Sharat Singh